ReviewClinical & developmental immunology2011
The confluence of stereotactic ablative radiotherapy and tumor immunology.
Review in Clinical & developmental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Pilot Study on PD-1 Inhibitors Consolidation After Standard First-line Chemotherapy and Radiotherapy in Extensive-stage Small Cell Lung Cancer
Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial
Who cites it
74 citing papers in PubMed, 165 citations in OpenAlex.
- Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.Radiation oncology (London, England) · 2016Trial
- Trial
- Effect of combining targeted therapies or chemotherapy with stereotactic radiosurgery (SRS) on the prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC).Journal of neuro-oncology · 2025Article
- Immune Modulation Through Stereotactic Radiotherapy: The Role of TBX21, GATA-3, FoxP3, and RORɣt.Medicina (Kaunas, Lithuania) · 2025Article
- To irradiate or electroporate: how should we ablate pancreatic cancer?Translational gastroenterology and hepatology · 2025Article
- Dynamic interactions in the tumor niche: how the cross-talk between CAFs and the tumor microenvironment impacts resistance to therapy.Frontiers in molecular biosciences · 2024Review
- Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.Current oncology (Toronto, Ont.) · 2023Review
- Brachytherapy for targeting the immune system in cervical cancer patients.BMC immunology · 2023Article
- Preliminary Results of the Effects of Localized High-Dose Radiotherapy Combined with Total Body Low-Dose Irradiation on Tumor Growth and Stimulating the Immune System in Tumor-Bearing Mice.Journal of biomedical physics & engineering · 2023Article
- Fractionated Stereotactic Radiotherapy with Helical Tomotherapy for Brain Metastases: A Mono-Institutional Experience.Journal of personalized medicine · 2023Article
- Article
- On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happenings.Cancer medicine · 2023Review
- Article
- Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma.Biomedicines · 2022Review
- Fifty-year history of the evolution of spinal metastatic disease management.Journal of surgical oncology · 2022Article
- The evolving role of radiation therapy as treatment for liver metastases.Journal of the National Cancer Center · 2022Review
- Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.Scientific reports · 2022Article
- Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions.Biomedicines · 2022Review
- Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.International journal of molecular sciences · 2022Review
- Innovations in radiotherapy and advances in immunotherapy for the treatment of brain metastases.Clinical & experimental metastasis · 2022Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), in the clinic due to advances in precise positioning and targeting. Dramatic improvements in tumor control have been demonstrated; however, our knowledge of normal tissue biology response mechanisms to large fraction sizes is lacking. Herein, we will discuss how SABR can induce cellular expression of MHC I, adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors to enhance antitumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.